New VP of Clinical and Regulatory Affairs for Intec Pharma

Pnina Strauss-Levy has broad experience in clinical development, regulatory affairs and business development

Intec Pharma, a clinical-stage biopharmaceutical company based in Jerusalem, Israel, has appointed Pnina Strauss-Levy as Vice President, Clinical and Regulatory Affairs.

Strauss-Levy has held several positions with Kamada, an Israeli pharmaceutical company, including Vice President, Clinical Development and IP. She has experience in clinical development, regulatory affairs and business development.

Strauss-Levy holds a BSc degree in Biochemistry and Food Sciences from the Hebrew University in Jerusalem and an MBA degree from the University of Derby in the UK.

Intec Pharma is developing drugs based on its proprietary Accordion Pill technology, an oral drug delivery system that aims to improve the efficacy and safety of existing drugs and drugs in development by using a gastric retention and specific release mechanism. The company's product pipeline currently includes three product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CDLD, which is being developed for treating Parkinson's disease; Accordion Pill Zaleplon, or AP-ZP, which is being developed for treating insomnia, and an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Designer pills and smart capsules that can deliver

Oral delivery of drugs remains a preferred route, and innovation in this field is at its most creative. Dr Sarah Houlton looks at some of the interesting options under development
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Subscribe now